\
&
Contact us
\
&
Contact us
This was 6 years ago
LocationCentre de conference Albert Borschette (CCAB)
Meeting room: 0/C
Rue Froissart 36
1050 Brussels
The European Commission will organise an Information Day to inform potential applicants about the Societal Challenge 6 Work Programme-“Innovative, reflective and Inclusive Societies” and its funding opportunities. This information day is an opportunity for attendees to get some insight into the Societal Challenge 6 calls for proposals of Horizon 2020, for the Work Programme of 2020, covering challenges on Migration, Socio-economic transformations and Governance. Speakers will discuss policy and will give advice and tips on preparing and submitting proposals, and on the financial aspects of funding. There will also be a chance to network and meet potential partners as well as to see examples of previously funded projects.
More information is available in the event announcement
The registration closes on 18 October 2019. Please apply by sending an email to RTD-H2020-SC6@ec.europa.eu. For a complete registration please send the following information:
A confirmation of your participation in the Info Days event will be sent to you by 20 October.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
